Integrating their expression profiles with clinical features—such as tumour stage, MSI status and common oncogenic mutations (e.g., TP53, KRAS, BRAF)—may help develop more robust and clinically applicable prognostic models. The gene discussed is TP53; the disease is neoplasm.